# PRQR catalysts: ProQR Therapeutics N.V. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/prqr/catalysts

> ProQR Therapeutics N.V. (PRQR) has 5 upcoming catalysts. The next is the AX-0811 interim data readout, Jan 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, year only, half-year only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | ProQR Therapeutics N.V. |
| Ticker | PRQR (Nasdaq) |
| SEC CIK | 1612940 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/prqr |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Feb 2022 | [Sepofarsen topline data readout](https://sec-api.dev/pdufa/sepofarsen) | PRQR |  | completed, missed | "In February 2022, we announced that top-line results from our Phase 2/3 pivotal trial of sepofarsen did not meet its primary endpoint." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1612940/000155837025002851/tmb-20241231x20f.htm)) |
| Q4 2025 | [AX-0810 trial start](https://sec-api.dev/pdufa/ax-0810) | PRQR |  | scheduled | "RNA editing technology platform, including the continued development and advancement of our Axiomer platform, the advancement of AX-0810 to clinical trials, including the timing of, and our ability to obtain regulatory clearance; our expectations regarding the initiation of the planned Phase 1 clinical study of AX-0810 in the Netherlands, including our ability to recruit for and complete the study, and the anticipated timing of initial data in Q4 2025; the plan, timing, progress and results of our preclinical studies, planned clinical trials and other development activities, including the release of data related thereto, and the potential of our technologies and product candidates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612940/000110465925063073/tm2519211d1_ex99-1.htm)) |
| Q4 2025 | [AX-0810 topline data readout](https://sec-api.dev/pdufa/ax-0810) | PRQR |  | scheduled | "We expect to share topline data from this trial in Q4 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1612940/000155837025002851/tmb-20241231x20f.htm)) |
| Q4 2025 | [AX-0810 interim data readout](https://sec-api.dev/pdufa/ax-0810) | PRQR |  | scheduled | "RNA editing technology platform, including the continued development and advancement of our Axiomer platform, the advancement of AX-0810 to clinical trials, including the timing of, and our ability to obtain regulatory clearance; our expectations regarding the initiation of the planned Phase 1 clinical study of AX-0810 in the Netherlands, including our ability to recruit for and complete the study, and the anticipated timing of initial data in Q4 2025; the plan, timing, progress and results of our preclinical studies, planned clinical trials and other development activities, including the release of data related thereto, and the potential of our technologies and product candidates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612940/000110465925063073/tm2519211d1_ex99-1.htm)) |
| 2026 | [AX-2911 topline data readout](https://sec-api.dev/pdufa/ax-2911) | PRQR |  | scheduled | "We intend to commence development activities for AX-2911 in 2025, including to select a development candidate for this program and initiate clinical trial in 2026, with topline data readout anticipated in 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1612940/000155837025002851/tmb-20241231x20f.htm)) |
| 2026 | [AX-2402 topline data readout](https://sec-api.dev/pdufa/ax-2402) | PRQR |  | scheduled | "Lead EON optimization is currently ongoing with the objective to select a clinical candidate for AX-2402 in 2025, and initiate clinical trial in 2026, with topline data readout anticipated in 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1612940/000155837025002851/tmb-20241231x20f.htm)) |
| 2026 | [ProQR Therapeutics N.V. topline data readout](https://sec-api.dev/companies/prqr/catalysts) | PRQR |  | scheduled | "Top-line data expected in 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612940/000110465924127611/tm2430675d1_ex99-1.htm)) |
| late 2026 | [AX-0811 interim data readout](https://sec-api.dev/pdufa/ax-0811) | PRQR |  | scheduled | "Pending CTA authorization, initial data with AX-0811 is anticipated by year end 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612940/000110465926095422/tm2622847d1_ex99-1.htm)) |
| late 2026 | [AX-0810 interim data readout](https://sec-api.dev/pdufa/ax-0810) | PRQR |  | scheduled | "ProQR expects to advance its first programs generated using its AI-enabled discovery approach into the clinic, with a clinical trial application (CTA) anticipated in mid-2026 and initial clinical data anticipated by year-end 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612940/000110465926040682/tm2611275d1_ex99-1.htm)) |
| late 2026 | [AX-0811 trial start](https://sec-api.dev/pdufa/ax-0811) | PRQR |  | scheduled | "our ability to obtain authorization for, initiate, enroll, and complete a Phase 1 clinical trial for AX-0811 and the anticipated timing of initial data readout by year end 2026, pending CTA authorization;" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612940/000110465926095422/tm2622847d1_ex99-1.htm)) |
| September 9, 2026 | [AX-0811 trial start](https://sec-api.dev/pdufa/ax-0811) | PRQR |  | completed | "Netherlands & CAMBRIDGE, Mass., September 9, 2026 - ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that the first participant has been dosed in the Phase 1 clinical trial of AX-0811 in healthy volunteers." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612940/000110465926106138/tm2624953d1_ex99-1.htm)) |
| Jan 2027 | [AX-0811 interim data readout](https://sec-api.dev/pdufa/ax-0811) | PRQR | biliary atresia in China prior | scheduled | "our ability to continue to enroll and complete the ongoing Phase 1 clinical trial for AX-0811 and the anticipated timing of initial data readout expected in early January 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612940/000110465926125795/prqr-ex99d2.htm)) |
| 1H 2027 | [AX-0810 interim data readout](https://sec-api.dev/pdufa/ax-0810) | PRQR | biliary atresia and to generate meaningful data therefrom | scheduled | "our ability to collaborate with investigators to initiate, conduct and recruit for an IIT of our NTCP program in China in pediatric participants with biliary atresia and to generate meaningful data therefrom, including the anticipated timing of initial data readout in the first half of 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612940/000110465926125795/prqr-ex99d2.htm)) |
| 1H 2027 | [ProQR Therapeutics N.V. interim data readout](https://sec-api.dev/companies/prqr/catalysts) | PRQR |  | scheduled | "ProQR is also continuing preparations for an investigator-initiated trial (IIT) in pediatric biliary atresia in China, with initial clinical data expected in the first half of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612940/000110465926125795/prqr-ex99d2.htm)) |
| 1H 2027 | [AX-0422 interim data readout](https://sec-api.dev/pdufa/ax-0422) | PRQR |  | scheduled | "●AX-0422 for MPS I Hurler Syndrome (IDUA) CTA filing for a first-in-patient study anticipated in early 2027 and initial data expected in the first half of 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612940/000110465926125795/prqr-ex99d2.htm)) |
| mid-2028 | [AX-0810 interim data readout](https://sec-api.dev/pdufa/ax-0810) | PRQR |  | scheduled | "the anticipated initiation of our potentially registration-enabling Phase 2 program in mid-2027 with first interim analysis data expected by mid-2028, subject to regulatory interactions" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612940/000110465926125795/prqr-ex99d2.htm)) |

## Drugs

- [AX-0422](https://sec-api.dev/pdufa/ax-0422): 
- [AX-0810](https://sec-api.dev/pdufa/ax-0810): biliary atresia and to generate meaningful data therefrom
- [AX-0811](https://sec-api.dev/pdufa/ax-0811): biliary atresia in china prior
- [AX-2402](https://sec-api.dev/pdufa/ax-2402): 
- [AX-2911](https://sec-api.dev/pdufa/ax-2911): 
- [Sepofarsen](https://sec-api.dev/pdufa/sepofarsen): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/prqr/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PRQR catalysts: ProQR Therapeutics N.V. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/prqr/catalysts

```bibtex
@misc{secapidev_companies_prqr_catalysts_20261116,
  title        = {PRQR catalysts: ProQR Therapeutics N.V. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/prqr/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_prqr_catalysts_20261116","title":"PRQR catalysts: ProQR Therapeutics N.V. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/prqr/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
